Evidence map›Paper›PMID 37439437›Full record

ArticleCancer science2023

Interferon-expressing oncolytic adenovirus + chemoradiation inhibited pancreatic cancer growth in a hamster model.

Shuhei Shinoda, Nikita S Sharma, Naohiko Nakamura, Kazuho Inoko, Mizuho Sato-Dahlman, Paari Murugan, Julia Davydova, Masato Yamamoto

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Exosome-mediated triple drug delivery enhances apoptosis in pancreatic cancer cells.Apoptosis : an international journal on programmed cell death · 2025
    Article
  6. Article
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 2 countries.

Shuhei ShinodaDepartment of Surgery, University of Minnesota, Minneapolis, MN, USA.ORCID https://orcid.org/0000-0002-4128-2177
Nikita S SharmaDepartment of Surgery, University of Minnesota, Minneapolis, MN, USA.
Naohiko NakamuraDepartment of Surgery, University of Minnesota, Minneapolis, MN, USA.
Kazuho InokoDepartment of Surgery, University of Minnesota, Minneapolis, MN, USA.
Mizuho Sato-DahlmanDepartment of Surgery, University of Minnesota, Minneapolis, MN, USA.
Paari MuruganDepartment of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA.
Julia DavydovaDepartment of Surgery, University of Minnesota, Minneapolis, MN, USA.
Masato YamamotoDepartment of Surgery, University of Minnesota, Minneapolis, MN, USA.
University of Minnesota · US

Funding

Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Timothy C. Hallstrom · 1998 to 2026
$100.4M
Combination therapy with IFN expressing oncolytic adenovirus for pancreatic cancerR01CA228760 · NCI · UNIVERSITY OF MINNESOTA · PI DAVYDOVA, JULIA, YAMAMOTO, MASATO · 2019 to 2023
$1.7M
Systemic Therapy with Infectivity-Selective Oncolytic Adenovirus for PDACR01CA196215 · NCI · UNIVERSITY OF MINNESOTA · PI YAMAMOTO, MASATO · 2016 to 2020
$1.7M
Advanced Oncolytic Adenovirus Enabling Systemic Therapy of PDACR01CA276480 · NCI · UNIVERSITY OF MINNESOTA · PI MASATO YAMAMOTO · 2023 to 2026
$1.4M
NCI NIH HHS P30 CA077598NCI NIH HHS P30CA077598-22S3NCI NIH HHS R01 CA196215NCI NIH HHS R01CA196215NCI NIH HHS R01 CA228760NCI NIH HHS R01CA228760NCI NIH HHS R01 CA276480NCI NIH HHS R01CA276480
6 · The paper itself

Abstract

Past clinical trials of adjuvant therapy combined with interferon (IFN) alpha, fluorouracil, cisplatin, and radiation improved the 5-year survival rate of pancreatic ductal adenocarcinoma (PDAC). However, these trials also revealed the disadvantages of the systemic toxicity of IFN and insufficient delivery of IFN. To improve efficacy and tolerability, we have developed an oncolytic adenovirus-expressing IFN (IFN-OAd). Here, we evaluated IFN-OAd in combination with chemotherapy (gemcitabine + nab-paclitaxel) + radiation. Combination index (CI) analysis showed that IFN-OAd + chemotherapy + radiation was synergistic (CI <1). Notably, IFN-OAd + chemotherapy + radiation remarkably suppressed tumor growth and induced a higher number of tumor-infiltrating lymphocytes without severe side toxic effects in an immunocompetent and adenovirus replication-permissive hamster PDAC model. This is the first study to report that gemcitabine + nab-paclitaxel, the current first-line chemotherapy for PDAC, did not hamper virus replication in a replication-permissive immunocompetent model. IFN-OAd has the potential to overcome the barriers to clinical application of IFN-based therapy through its tumor-specific expression of IFN, induction of antitumor immunity, and sensitization with chemoradiation. Combining IFN-OAd with gemcitabine + nab-paclitaxel + radiation might be an effective and clinically beneficial treatment for PDAC patients.

Indexed as

Adenoviridae InfectionsCarcinoma, Pancreatic DuctalPancreatic NeoplasmsAdenoviridaeAlbuminsAnimalsAntineoplastic Combined Chemotherapy ProtocolsCell Line, TumorCricetinaeHumansInterferon-alphaPaclitaxelVirus ReplicationAlbuminsInterferon-alphaPaclitaxelinterferon alphanab-PTXoncolytic adenovirusoncolytic viruspancreatic cancer

Identifiers

PMID37439437
PMCPMC10475772
OpenAlexW4384126731

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.